| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Interim CFO
1 company
Kameel D. Farag is Interim CFO at AKTX. Kameel D. Farag's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $190K at current prices.
Kameel D. Farag has 7 Form 4 filings on record from October 2025 to August 2026, across 2 companies: Interim CFO at Akari Therapeutics (AKTX), 2025–2026; Director at Biovie (BIVI), 2026.
The 15 reported transactions were 12 stock awards, 2 open-market purchases and 1 option or other derivative award.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
No transactions found
Try adjusting your filters or search criteria